These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9226730)

  • 1. Nullification of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice.
    Shikimi T; Inagaki T; Kaku K; Ishino H; Okunishi H; Takaori S
    Psychoneuroendocrinology; 1997 May; 22(4):269-75. PubMed ID: 9226730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nullification of a positive correlation between urinary contents of alpha1-microglobulin and ulinastatin with intracerebroventricularly administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium (MPP+) in mice.
    Kaku K; Shikimi T; Kamisaki Y; Inagaki T; Ishino H; Okunishi H; Takaori S
    Psychopharmacology (Berl); 1998 Apr; 136(4):374-8. PubMed ID: 9600583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the ratio of urinary alpha 1-microglobulin to ulinastatin levels in patients with Alzheimer-type dementia and vascular dementia.
    Inagaki T; Shikimi T; Ishino H; Okunishi H; Takaori S
    Psychiatry Clin Neurosci; 1995 Dec; 49(5-6):287-90. PubMed ID: 8726115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impairment of the correlation between urinary contents of alpha-1-microglobulin and ulinastatin is induced by intracerebroventricularly administered interleukin-6 in mice.
    Kaku K; Shikimi T; Inagaki T; Ishino H; Okunishi H; Takaori S
    Neuropsychobiology; 1999; 40(1):33-9. PubMed ID: 10420099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-existence of a positive correlation between urinary levels of alpha 1-microglobulin and ulinastatin in patients with Parkinson's disease.
    Inagaki T; Shikimi T; Matsubara K; Kobayashi S; Ishino H; Okunishi H; Takaori S
    Psychiatry Clin Neurosci; 1996 Aug; 50(4):231-3. PubMed ID: 9201781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L; Frohna PA; Joyce JN; Schneider JS
    Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M; Goulet M; Calon F; Falardeau P; Blanchet PJ; Bédard PJ; Di Paolo T
    Mol Pharmacol; 1996 Nov; 50(5):1073-9. PubMed ID: 8913337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
    Goshima Y; Misu Y; Arai N; Misugi K
    Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
    Zhang QS; Heng Y; Mou Z; Huang JY; Yuan YH; Chen NH
    Acta Pharmacol Sin; 2017 Oct; 38(10):1317-1328. PubMed ID: 28649132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
    Riahi G; Morissette M; Parent M; Di Paolo T
    Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
    Fredriksson A; Palomo T; Chase T; Archer T
    J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
    Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.